Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15 2024 - 8:00AM
Fate Therapeutics, Inc. (the “Company” or “Fate
Therapeutics”) (NASDAQ: FATE), a clinical-stage
biopharmaceutical company dedicated to bringing a first-in-class
pipeline of induced pluripotent stem cell (iPSC)-derived cellular
immunotherapies to patients with cancer and autoimmune disorders,
today announced that the Company will host a conference call and
live audio webcast on Monday, February 26,
2024 at 5:00 PM ET to report its fourth quarter and
full year 2023 financial results and provide a corporate update.
In order to participate in the conference call, please register
using the conference link here. The live webcast
can be accessed under "Events & Presentations" in the Investors
section of the Company's website at www.fatetherapeutics.com.
The archived webcast will be available on the Company's website
beginning approximately two hours after the event.
About Fate Therapeutics, Inc.Fate
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune disorders. Using its
proprietary iPSC product platform, the Company has established a
leadership position in creating multiplexed-engineered iPSC lines
and in the manufacture and clinical development of off-the-shelf,
iPSC-derived cell products. The Company’s effector cell pipeline
includes multiplexed-engineered, iPSC-derived natural killer (NK)
cell and T-cell product candidates, which incorporate novel
synthetic controls of cell function, such as chimeric antigen
receptors (CARs) to target tumor-associated antigens, and are
intended to deliver multiple mechanisms of therapeutic importance
to patients including in combination with well-established cancer
therapies. Fate Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor
Relations,
Inc.212-362-1200christina.tartaglia@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024